Better Dividend: Merck or Pfizer?

Merck's (NYSE: MRK  ) dividend yield is 4.2%. Pfizer's (NYSE: PFE  ) is only 3.5%. Merck's is higher so it must be a better choice for dividend investors.

Not so fast.

Unless you're content with a 4.2% yield, and you're convinced that it can last long, you have to dig beyond the dividend yield to see which drugmaker is a better stock to own.

A little history
Neither company has a stellar track record when it comes to dividends. They don't compare to Abbott Labs (NYSE: ABT  ) , which raised its dividend for 40 years in a row, and probably would have continued the trend had it not spun off its pharmaceutical division into AbbVie (NYSE: ABBV  ) , sending a good chunk of its cash flow with it. Both Abbott and AbbVie will likely continue the tradition of raising their dividends, but they'll do it from smaller individual bases.

Pfizer cut its dividend in half when it decided to purchase Wyeth in 2009. Since then, it's made four dividend raises, but its dividend of $0.24 per quarter is still well below the $0.32 per quarter it handed out before the cut.

Merck hasn't cut its dividend recently, but it doesn't have a long history of raising it either. Merck's dividend was frozen at $0.38 per quarter after Vioxx went off the market in 2004, until 2011, when Merck finally raised the dividend. It was raised again last year to the $0.43 it currently sits at.

Based on the free cash flow and dividends from the most recent reporting period -- fourth quarter 2011 through third quarter 2012, because neither company has filed their 10-K for 2012 yet -- it appears that both companies should have no problem funding the dividend in the future.

Company

Dividend Payments TTM (in millions)

Free Cash Flow TTM (in millions)

Payout Ratio

Pfizer

$6,439

$15,628

41%

Merck

$5,001

$9,667

52%

Source: S&P Capital IQ.

Beyond the dividend
Investors shouldn't be content with just the dividends. While the dividends pay out like a fairly nice bond, owning the stock comes with increased risk compared to a bond. You really need to supplement the dividend with capital appreciation of the stock to make owning either durgmaker worthwhile. Holding a large pharma isn't risk free -- Vioxx anyone? -- so investors need to be rewarded for it; 3% to 4% return isn't going to cut it.

Figuring out which company will increase its valuation is a little more complicated than analyzing the prospects for the dividend. There's a lot of moving parts: revenue growth from current drugs, the company's pipelines, drugs going off patent, changes in margins.

Take them all together, and I see Pfizer faring better in the medium term than Merck.

Both companies are struggling with the loss of key drugs to generic competition, Lipitor for Pfizer, and Singulair for Merck. Pfizer's revenue in the fourth quarter was down 10%; Merck's was down 4.5 %

The difference is that Pfizer has a potential savior already on the market. Its blood thinner Eliquis, which it will sell with Bristol-Myers Squibb (NYSE: BMY  ) , was approved late last year to treat patients with atrial fibrillation, one of the most common types of abnormal heart rhythm. In clinical trials, Eliquis trounced warfarin, a drug that doctors hate because it's difficult to find a dose that's effective, but doesn't cause excessive internal bleeding. Grabbing a majority of the market shouldn't be too tough, although it may take awhile, because doctors probably aren't going to switch many patients taking warfarin if their dose appears to be working.

Merck's best shot at a megablockbuster is its osteoporosis drug, odanacatib. But the company said a few weeks ago that it wants to wait for long-term safety data before making regulatory applications, pushing an FDA approval into next year. The potential of the drug isn't as clear as that of Eliquis, because there's a lot of competition in the osteoporosis market, including cheap generic drugs.

As long as Eliquis reaches its full potential, Pfizer should have a quicker return to solid earnings and revenue growth than Merck. And that should translate to an increase in share price and, hopefully, increased cash flow that the company shares with investors in the form of increased dividends.

Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, the Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more -- and get a full year of free updates -- click here to claim your copy today.


Read/Post Comments (1) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 16, 2013, at 11:22 AM, willy325 wrote:

    Thank you. That was informative for me. Without input from people like you investors would be in the dark.

Add your comment.

DocumentId: 2259561, ~/Articles/ArticleHandler.aspx, 4/19/2014 8:38:44 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement